Bhopal: The nasal Covid-19 vaccine from Bharat Biotech, known as the iNCOVACC, is anticipated to be on sale on January 26. Executive chairman Krishna Ella announced this during a gathering on Saturday.
A primary two-dose schedule and a heterologous booster dosage for iNCOVACC have been approved.
Ella announced to students at the Maulana Azad National Institute of Technology in Bhopal, where the India International Science Festival, 2022, is being organised, that “our nasal vaccine will be officially launched on January 26 on Republic Day.”
The launch of Lumpi-ProVacInd, a locally developed vaccine, is also anticipated for the following month, according to Ella.
The pharmaceutical business, which created the intramuscular coronavirus vaccine Covaxin, had previously stated in December that its nasal vaccine will be available by the fourth week of January.
According to Bharat Biotech, the cost of iNCOVACC will be Rs 325 per dose for bulk purchases by the federal and state governments and Rs 800 per dose for commercial vaccination clinics. Regardless of the first immunisation dose, the vaccine will be administered as a booster shot to everyone above the age of 18. Two doses will be given, separated by 28 days.
The Central Drugs Standard Control Organization approved the nasal vaccination in December. Later that month, the National Technical Advisory Group on Immunization in India suggested adding it to the list of “precautionary doses” that adults can take as boosters.
Read More: Narwal Twin Blast Injures Nine, Bomb Squad at Spot; Panic Amid Rahul Gandhi’s J&K Yatra
Nine locations around the nation hosted the 875 participants in the nasal clinical trials. The vaccine was created in collaboration with Washington University in St Louis, which created the recombinant adenoviral vectored construct and tested its effectiveness in preclinical tests, according to a previous statement from Bharat Biotech.
On Saturday, Ella added that the debut of Lumpi-ProVacind, created by the Indian Council of Agriculture Research, is anticipated for the following month.
The council and Bangaluru-based Biovet, a subsidiary of Bharat Biotech, had a contract in place for the commercial production of the vaccine in September of last year.
